The first ever copper-gold focused drilling program at the northern portion of the Nyngan Project will shortly commence with earn-in partner AngloGold Ashanti Australia (AngloGold Ashanti).New district-scale potential with up to eight large intrusive complex targets to be drill-tested for the first time in this initial first phase program.Approximately 6 to 8 drill holes for an estimated 4000-5000 metres budgeted before the summer break. Kincora is managing the program and will receive a 10% management fee. The program is the first by Kincora in partnership with AngloGold Ashanti, which has the right to spend up to A$50 million to earn an 80% interest in the Nyngan and Nevertire Projects.Fleet Space Technologies Pty Ltd's (Fleet Space) ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys at the Nyngan Project are progressing well and are expected to complement upcoming drilling.Melbourne, Australia--(ACN Newswire via SeaPRwire.com - August 14, 2024) - Kincora Copper Limited (TSXV: KCC) (ASX: KCC), (Kincora or the Company) is pleased to outline plans for the next chapter of copper-gold focused drilling in the Macquarie Arc, Central West New South Wales (NSW) with a first program in partnership with and funded by AngloGold Ashanti to shortly commence at the Nyngan Project.Sam Spring, President and CEO of Kincora, commented: "We are very excited by the potential of the Northern Junee-Narromine belt where we are seeking not to just confirm a new significant porphyry Cu-Au deposit but a new district and series of discoveries. The strategic appeal and value of a new porphyry district has been clearly illustrated in the Vicuña district with corporate activities by BHP and Lundin Mining this month supporting over C$8 billion of value being recognised for a cluster of four new major discoveries. Recent planning and targeting activities with our partner AngloGold Ashanti has significantly expanded the number of targets, the drilling activities needed and planned to test a series of major and previously undrilled interpreted magmatic complex targets at the Nyngan Project. Initially we are aiming to test up to eight new major intrusive system complex targets before year end in this first phase program which focuses on the very compelling northern Nyngan "Ace of Spades" region.Recent neighbouring explorer drilling is also supporting the potential of a series of Macquarie Arc intrusive complexes to the immediate east of the "Ace of Spades" target area along a potentially important common transverse structure providing further encouragement to the potential of a new porphyry district scale opportunity."BackgroundThe undercover extensions of the renowned Macquarie Arc porphyry copper-gold geology are globally significant exploration opportunities offering new district(s) scale discovery potential. The region has attracted four earn-in and joint venture agreements in the last 12 months supporting potentially over $200 million in exploration and development expenditure.The most recent notable example of a new emerging globally significant porphyry district is the Vicuña district in the central Andes in Argentina on the border of Chile, which is largely consolidated by Lundin group entities and BHP and situated at over 4000m altitude 1.Within this district NGEX Resources Inc in 2009 held three early-stage exploration projects and, at the time, had a market capitalisation of approximately C$40 million. These same projects are all still at a pre-development phase but have yielded four large-scale discoveries currently valued at over C$8 billion 2.In comparison, the central west of NSW benefits from multiple world-class mines, existing infrastructure, high-quality publicly available exploration data and an existing mineral endowment of over 160 million gold equivalent ounces 3. Regional geophysics strongly indicates that Kincora's Nyngan license hosts the largest volcano-intrusive complex of the Macquarie Arc, which is almost untested, offering new district scale potential.Kincora, as the early entrant, has secured a district scale position in the interpreted shallow-to-moderate covered core sections of the Northern Junee-Narromine Belt (NJNB) by pegging Nyngan and Nevertire which are now in partnership with AngloGold Ashanti 4.The imminent first-ever drilling program at the northern portion of the Nyngan Project will focus on the "Ace of Spades" region and test a wide range of untested, large intrusive-related Cu-Au targets. The program seeks to confirm the potential for a series of new Macquarie Arc intrusive complexes and provide vectors for follow up drilling - see Figure 1.Subject to permitting, access and weather conditions, the drilling program is anticipated to commence from mid September and will continue until the summer break, comprising up to eight holes for an estimated 4000-5000 metres.Recent planning and targeting activities with our partner AngloGold Ashanti have significantly expanded the number of targets, the drilling necessary to test a series of major and previously-undrilled interpreted magmatic complex targets at the Nyngan Project. This first program will test the potential for up to eight separate large intrusive complex targets.The program will comprise cost-effective mud-rotary drilling through the post mineral cover sequence with diamond core drilling upon refusal and testing of the targeted basement.Kincora is managing the exploration program and will receive a 10% management fee as the program is funded by AngloGold Ashanti via the up to $50 million earn-in and joint venture agreement for the Nyngan and Nevertire Projects.These drill targets include an existing high priority large intrusive complex target, which is currently the focus of Fleet Space's ongoing Ambient Noise Tomography (ANT) and gravity geophysical surveys within the northern portion of the Nyngan Project 5. Figure 1: District-scale series of major and untested magmatic complex targets with in the northern Nyngan "Ace of Spades" region that potentially represent the largest volcano-intrusive complex of the Macquarie Arc. Kincora is managing the exploration program and will receive a 10% management feeTo view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/219846_kincora.jpgThe geophysical surveys are seeking to map and refine the interpretation of the paleo-surface and basement rocks and refine modeling of the targeted alteration, intrusions and structures.Recent neighbouring exploration drilling by Inflection Resources ("Inflection") is further supporting the potential of a series of Macquarie Arc intrusives to the immediate east of the "Ace of Spades" target area at Nyngan. Inflection has announced encouraging results at the Canonba target situated on the license boundary to the Nyngan Project, and located approximately 5km from its Duck Creek target, which is a Phase 2 designated project with its earn-in and joint venture partner AngloGold Ashanti 6. The Canonba, Duck Creek and Ace of Spades target areas potentially host important common transverse structures providing further encouragement about the potential of a new district-scale porphyry opportunity.About the Nyngan ProjectThe Nyngan license (Exploration Licence 8929) was the first ground Kincora secured in NSW. It is a large 762km2 direct application tenement granted by the NSW State Government covering a significant portion of the interpreted under cover section of the northern Junee-Narromine Belt 7. The Junee-Narromine Belt is one of the two largest belts of the Macquarie Arc, Australia's foremost porphyry belt, which hosts a mineral endowment of over 160 million gold equivalent ounces.The license hosts limited, but encouraging, prior explorer drilling that has been inadequately followed up, with regional geophysics supporting a new potential district-scale setting hosting interpreted, large-scale, intrusive complex targets.In May 2024, Kincora signed a definitive multiple-phase Earn-in and Joint Venture Agreement (Agreement) over the Nyngan and Nevertire licences with a wholly owned subsidiary of AngloGold Ashanti plc (NYSE: AU) (JSE: ANG), the world's fourth largest gold miner by production, which has a successful track record for Greenfields discovery success.AngloGold Ashanti has the right to spend up to A$50 million to earn an 80% interest through:A$25 million of exploration expenditure to earn a 70% joint venture interest (Phase I) including a minimum A$2 million expenditure obligation, with Kincora the initial operator for a 10% management fee. Completion of a Pre-Feasibility Study (PFS) or funding of a further $25 million of expenditure to earn a 80% joint venture interest (Phase II).In July 2024, separate to the Agreement with AngloGold Ashanti, Kincora formed a partnership with Fleet Space Technologies Pty Ltd (Fleet Space) to undertake Ambient Noise Tomography (ANT) and gravity geophysical surveys under a research and development grant at the Nyngan Project.Within the immediate district Fleet Space recently completed the world's largest ANT survey, undertaking a number of project-specific surveys that defined multiple new targets and built a proprietary AI-powered district-scale copper prospectivity map 8,9,10.The Fleet Space surveys are anticipated to complement Kincora and AngloGold Ashanti's planned exploration and upcoming drilling.About KincoraKincora Copper is dual listed on the ASX and TSX-V (ticker "KCC") and is an active explorer and project generator focused on world-class copper-gold discoveries. The company recently executed four agreements that unlock up to A$60 million in multiple year partner funding. Further new projects that offer a clear value path and targeted partnerships are proposed.Kincora's portfolio includes district scale landholdings and scalable drill-ready targets in both Australia and Mongolia's leading porphyry belts, the Macquarie Arc and Southern Gobi, respectively, and, the Company is targeting initial exposure to 10,000m of drilling in the next 6-month before ramping up to over 30,000 metres pa of drilling.For more information please visit Kincora's website at www.kincoracopper.comReferences:1 Lundin Mining and BHP to Acquire Filo and Form a 50/50 Joint Venture to Progress the Filo del Sol and Josemaria Projects - BHP and Lundin Mining press releases July 29, 20242 NGEX Minerals Corporate Presentation (July 2024) and market values as at July 29, 2024 (from peer transactions and TSXV market capitalization)3 Sourced from MinEx Consulting for Kincora4 AngloGold Ashanti to earn-in to the NJNB Project - Kincora press release May 28, 20245 ANT and Gravity Geophysical Surveys at the Nyngan Project - Kincora press release July 25th, 2024 6 Inflection Resources provides drilling update from Phase 1 Exploration Program in NSW - Inflection press release July 30th, 2024 7 Kincora secures strategic license in Australia's leading porphyry belt - Kincora press release November 21, 20198 ANT geophysics defines additional epithermal-porphyry targets at Spur Project - Waratah press release May 23, 20249 Reimaging porphyry copper exploration using Exosphere: Ambient Noise Tomography from the Duck Creek project, Macquarie Fleet and Inflection Case Study 2023 10 Completes 1,800Km2 Ambient Noise Tomography Survey Across Portfolio of Projects in New South Wales - Inflection press release July 10, 2024This announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Executive office 400 - 837 West Hastings Street Vancouver, BC V6C 3N6, Canada Tel: 1.604.283.1722 Fax: 1.888.241.5996Subsidiary office AustraliaVista AustraliaLevel 4, 100 Albert RoadSouth Melbourne, Victoria 3205Qualified PersonThe scientific and technical information in this announcement was prepared in accordance with the standards of the Canadian Institute of Mining, Metallurgy and Petroleum and National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and was reviewed, verified and compiled by Kincora's staff under the supervision of Peter Leaman (M.Sc. Mineral Exploration, FAusIMM), Senior Vice-President of Exploration of Kincora, and John Holliday (BSc Hons, BEc, member of the Australian Institute of Geoscientists), Non-Executive Director and Chairman of Kincora's Technical Committee, who are Qualified Persons for the purpose of NI 43-101.JORC Competent Person StatementInformation in this announcement that relates to Exploration Results, Mineral Resources or Ore Reserves are those that have been previously reported (with the original release referred to in this announcement), in the case of Mineral Resources or Ore Reserves the material assumptions and technical parameters underpinning the estimates have not materially changed, and have been reviewed and approved by Paul Cromie, who is a Competent Person under the definition established by JORC and has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaking to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. John Holliday and Peter Leaman consents to the inclusion in this report of the matters based on his information in the form and context in which it appears. The review and verification process for the information disclosed herein for the Nyngan Projects have included the receipt of all material exploration data, results and sampling procedures of previous operators and review of such information by Kincora's geological staff using standard verification procedures.Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219846 Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your presence is the greatest protection for my love. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6022 1715Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) is pleased to announce that the Company is selected as a constituent to the MSCI Global Micro Cap Index (MSCI Hong Kong Micro Cap Index), with effect from the market close of 30 August 2024 (Friday).Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “We are confident that the Group's inclusion in the MSCI Hong Kong Micro Cap Index reflects the capital market’s appreciation of our business strategy and operational excellence. This development is anticipated to draw increased investor interest in the Group's growth prospects, potentially leading to a broader shareholder base. Looking ahead, we are actively enhancing our product portfolio and continuing to provide shareholders with greater value.”The MSCI Global Micro Cap Index captures micro cap representation across 23 developed markets countries. With 6,406 constituents, the index covers approximately 1% of the free float-adjusted market capitalization in each country. Assessments for the index are based on key factors, including minimum market capitalization, free float and liquidity, foreign inclusion factor requirement, and minimum length of trading requirement.- End -About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and Mainland China, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Mainland China market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first-and second-tier cities. In addition, Nissin Foods operates business in other Asian regions including Vietnam, Taiwan and Korea markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年8月14日 - (亚太商讯 via SeaPRwire.com) – 日清食品有限公司（「日清食品」或「公司」，连同其附属公司统称「集团」；股份代号：1475）欣然宣布集团已获纳入MSCI全球微型股指数（MSCI香港微型股指数），将于2024年8月30日（星期五）生效。日清食品执行董事、董事长兼首席执行官安藤清隆先生表示：「我们相信，集团被纳入MSCI香港微型股指数，体现了资本市场对我们业务策略和营运卓越的认可。我们预计，是次发展将吸引更多投资者对集团的增长潜力产生兴趣，并有机会带来更广泛的股东基础。展望未来，我们会积极丰富产品组合，并持续为股东提供更大价值。」MSCI全球微型股指数涵盖了23个已开发市场国家的微型市值代表性。该指数包括6,406个成分股，大致涵盖了每个国家约1%的自由流通市值。该指数的评估乃基于多个关键因素，包括最低市值、自由流通股及流动性、外国投资者持股比例要求，以及最短交易时间要求。– 完 –有关日清食品有限公司日清食品有限公司（「日清食品」，连同其附属公司统称「集团」；股份代号：1475）为一间在中国内地及香港知名的食品公司，主要专营优质方便面市场，旗下众多品牌不仅知名度高，且广受顾客喜爱。集团于1984年正式于香港设立营业据点并为香港最大的方便面公司。集团主要生产及销售两个核心企业品牌「日清」及「公仔」，以及多元化的家庭食品品牌组合，出品具标志性和优质的方便面、优质冷冻食品（包括冷冻点心及冷冻面条）并销售和分销其他食品及饮料产品（包括蒸煮袋装产品、零食、矿泉水、酱料及蔬菜产品）。集团五个旗舰品牌「合味道」、「出前一丁」、「公仔面」、「公仔点心」及「福」在香港亦是其各自食品类别中最受欢迎的选择。中国内地市场方面，集团以创新技术推出「ECO杯」概念，销售活动主要集中在中国内地的一线及二线城市。日清食品被纳入5项恒生指数，包括恒生综合指数、恒生综合小型股指数、恒生综合行业指数-必需性消费、恒生港股通消费行业指数和恒生港股通必需性消费指数。日清食品现可通过沪港通及深港通下港股通进行交易。详情请浏览www.nissingroup.com.hk。 Copyright 2024 亚太商讯 via SeaPRwire.com.

MELBOURNE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Mark your calendars for an unmissable event! We are thrilled to announce our partnership with the upcoming Modern DevOps Melbourne, taking place on October 8, 2024, at the prestigious Grand Hyatt Melbourne. This event promises to be a cornerstone for industry leaders and innovators in the DevOps community.Join us at Corinium's Modern DevOps Melbourne 2024, where you will have the opportunity to transform your DevOps delivery and explore revolutionary realms of platform engineering, DevSecOps, AI, and ModelOps. This is your chance to gain an unparalleled competitive edge in the ever-evolving tech landscape.We are extending a special invitation to all ACN Newswire via SeaPRwire.com readers, offering an exclusive discount code to join this invaluable industry gathering. Don't miss the chance to find inspiration, build new connections, and be part of a transformative experience.Get an exclusive $500 off the regular price by entering discount code DEVOPSPAR500 at checkout when registering.Keynote Speakers Include:Tim Baird, Senior Manager - DevOps, AIAMathangi VijayShankar, Engineering Lead API, MedibankAndrew Cunningham, Application Development & DevSecOps Team Lead, Australian Red Cross LifebloodJack Latrobe, Enterprise Architect – Sustainability External Relations & Legal, TelstraSerge Ambrose, Digital Technology Head – APAC, MMG LimitedAya Omar, Senior Manager Quality Engineering, WestpacParidhi Jha, Principal Machine Learning Engineer, Wesfarmers OneDigitalDave Lemphers, CTO, EasyGoNimisha Balyan, Chapter Lead, TelstraShivansh Sharma, Senior Manager Engineering - Platform & Reliability, TabcorpPouya Ghotbi, Security Lead APJ, AWSOlga Mirensky, Senior Platform Engineer, ANZNigel Fernandes, VP/GM Engineering (Ecosystem, Cloud, Platforms, Identity), XeroSean Duxbury, Principal Engineer – Google Cloud Platform, IAGDarragh Kennedy, Director of Engineering, ZendeskMichael Fornaro, Lead Cloud Engineer, ANZKey Themes at Modern DevOps Melbourne 2024:Maturing DevOps DNA: Elevate practices for greater efficiency and innovation in the software development lifecycle.Advance Your Toolchain with Automation, AI, and ML: Enhance scalability and efficiency in IT delivery.Bridging Legacy to Cloud: Unlock agility, scalability, and efficiency in modern DevOps practices.Unleash DevSecOps: Seamlessly integrate security measures into DevOps workflows.From Pipelines to Possibilities: Maximize the potential of CI/CD and deployment pipelines for DevOps velocity.This is an unparalleled opportunity to turbocharge scalable and secure DevOps deployment while aligning cyber and business strategies from a high-level perspective. Don't miss out on this chance to be part of Modern DevOps Melbourne!Register today: https://bit.ly/4ci5VsxAbout Corinium IntelligenceCorinium Intelligence is a global leader in providing conferences, events, and content to the information and technology industries. With a focus on fostering collaboration and innovation, Corinium Intelligence brings together industry leaders to share insights, best practices, and strategies for success.For more information, please contact Moira Ungerleider at moira.ungerleider@coriniumgroup.com. Copyright 2024 ACN Newswire via SeaPRwire.com.

SINGAPORE, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive "Lovers" collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair.ALUXE has upheld a customer-centric approach, providing each customer with the finest products and services. ALUXE is committed to crafting captivating jewellery and spreading happiness to countless couples worldwide.The 2024 collection features 8 captivating new designs, set to debut just before the Chinese Valentine’s Day. Adorned with rare and eternal blue diamonds, these pieces symbolise purity and enduring love. Inspired by bridal bouquets and veils, the designs combine simplicity with sophistication, creating unique and extraordinary works of art.Each ring in the "Lovers" collection is a testament to the purest form of love between two people. With these rings, ALUXE seeks to turn fleeting moments of happiness into cherished memories. The eternal blue diamonds in the new designs represent both purity and everlasting love, with each stone symbolising the unwavering commitment and sincerity between lovers. Every ring embodies the essence of “Every moment with you is a moment of love,” capturing the spirit of shared romantic journeys. Each ring also features a discreetly embedded blue sapphire inside, adding a touch of understated elegance.ALUXE’s exceptional craftsmanship ensures that every ring is not only beautiful but also unique. The meticulous attention to detail and superior craftsmanship provide exceptional comfort, while the minimalist design maintains a refined sophistication, making these rings perfect for any occasion.To celebrate the launch of the new collection, ALUXE is offering complimentary personalised engravings for a limited time. These bespoke engravings add a personal touch, making the rings even more special and memorable.Chinese Valentine’s Day, a day dedicated to love and promises, is the perfect occasion to introduce the new "Lovers" collection. These wedding rings are ideal for couples looking to celebrate their love and make a lifelong commitment. Let the "Lovers" collection accompanies every love story, adding a touch of romance to each chapter.Discover the new "Lovers" series at ALUXE stores or visit our website to view the complete collection. Celebrate your love with a ring that symbolises the purest and most enduring moments of your relationship.Lovers Series – The moments of loveThe "purity" of blue diamonds is like the sincere love between lovers. The " brilliance " of blue diamond’s tells the sparkle of every romantic moment. The "blue" of blue diamonds is the foundation of trust and security between lovers. Blue is both infnite and eternal. Each unique blue diamond turns the happiness between lovers into eternity. Every moment with you is the moment of love.Design Features:I am willing to walk alongside you all the way, supporting each other and shining in our own ways. The curve of the ring symbolises the love of two people running towards each other, while the blue diamond represents the figures on their growth path. Together, they grow into braver and more resilient soulmates, telling the story of a sweet and brilliant love between lovers.Lovers Collection - Blue Diamond Engagement Ring (RS2010)The curved bands on both sides extend to the centre, where the main diamond is set. Just like our love, it takes two people holding hands tightly to achieve happiness.RS2010Platinum SGD 2,520(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0010):The matching rings feature a streamlined design that symbolises a love journey where both sides meet each other halfway. The man's ring has a calm, brushed texture, while the woman's ring is adorned with diamonds, representing hopes and dreams for the future. The blue diamond symbolises the couple walking side by side, experiencing both joys and challenges together, each shining in their unique way.RB0010Platinum SGD 2,090RG0010Platinum SGD 2,140 Design Features:Your gentleness is my greatest safeguard in this life. Inspired by a bouquet, it elegantly cradles the main diamond. A flowing line on the ring symbolises the unique mark of love, writing the story of a steady and enduring romance between two people.Lovers Collection - Blue Diamond Engagement Ring (RS2018):The main diamond ring is designed like a bouquet, symbolising the blossoming of our love and the beginning of a new chapter in life together. The blue diamonds on either side of the main diamond represent the two of us, steadfastly protecting this miraculous love.RS2018Platinum SGD 1,980(Excluding Diamond) Lovers Collection - Blue Diamond Wedding Ring (RBG0018)A sleek, simple line on the ring band symbolises the story of our enduring love, like the unspoken understanding and eternity between us. From now on, whether in moments of brilliance or in everyday life.RB0018Platinum SGD 2,090RG0018Platinum SGD 1,770 Design Features:The blue diamond represents the most brilliant moment between us, a fleeting instant turned eternal. It carries the love memories of two people through time. As sunlight falls, it reflects our every moment of happiness and sweetness.Lovers Collection - Blue Diamond Wedding Ring (RBG0009)The blue diamond symbolises our most brilliant moment, eternal in an instant. Forever in our hearts, the ring band is like a steady shoulder, protecting that brilliant memory and expressing your unwavering and understanding love.The blue diamond captures our happiness, making a moment eternal. The row of diamonds represents the countless love memories we share over time. Worn every day, it shines with infinite beauty.RB0009Platinum SGD 2,320RG0009Platinum SGD 1,780 For Media Queries, Please Contact:Chua Sheng Rui: +65 9137 2102 // shengrui@swstrategies.orgAmirul Asyraf: +65 8448 4824 // amirul@swstrategies.orgAbout ALUXEALUXE is the first jewellery brand in Taiwan, embodying the perfect combination of happiness and jewellery. Starting as an online retailer, ALUXE's high-quality products and competitive prices gradually garnered more attention, which led to the opening of its first physical store in 2008 to offer even better products and services to customers around the world. ALUXE is currently present in Taiwan and Hong Kong, with Singapore’s flagship store located at ION Orchard and two other doors at the heartland areas.For more information, visit https://www.aluxe.com/FB: https://www.facebook.com/aluxe.sgIG: https://www.instagram.com/aluxe_sg/Whatsapp: +65 8189 7721ALUXE LocationsION Orchard2 Orchard Turn, ION Orchard #B2-63, Singapore 238801Tel: +65 6015 0798Opening Hours: 10:00 - 21:30JEM50 Jurong Gateway Road, JEM #01-55, Singapore 608549Tel: +65 6992 2589Opening Hours: 11:00 - 21:30Tampines 110 Tampines Central 1, Tampines 1 #01-27 & 28, Singapore 529536Tel: +65 6992 2589Opening Hours: 11:00 - 21:30 Copyright 2024 ACN Newswire via SeaPRwire.com.

Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs.- In the first half of 2024, the Group's revenue from innovative products reached RMB 6.13 billion, a year-on-year increase of 14.8%. In addition to innovative products, the Group has 11 generic drugs approved by the NMPA for market launch. The overall revenue of generic drugs achieved positive growth in the first half of 2024. New products are an important driver of the Group’s revenue growth. In the first half of 2024, the Group’s revenue from new products launched within five years reached RMB 6.03 billion, representing a year-on-year increase of 39.6%.- As of 30 June 2024, the Group had a total of 43 innovative drug candidates in the field of oncology, 8 innovative drug candidates related to the respiratory system, 6 innovative drug candidates related to liver disease, and 4 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 3 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 5 innovative oncology drug candidates, 1 innovative respiratory system drug candidate, 1 innovative liver disease drug candidate, and 1 innovative surgery/analgesia drug candidates are in Phase III clinical trials. In addition, the Group had a total of 18 biosimilar or generic drug oncology candidates, 3 additional biosimilar or generic liver disease drug candidates, 21 biosimilar or generic respiratory system drug candidates, and 10 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. In February and July 2024, for anlotinib in combination with benmelstobart, two marketing applications were submitted to the Center for Drug Evaluation (“CDE”) of NMPA for the treatment of second- and third-line endometrial cancer, and first line renal cell carcinoma, respectively. In July 2024, the Phase III clinical study of anlotinib in combination with chemotherapy for the first-line treatment of advanced soft tissue sarcoma achieved positive results. The Group has submitted the marketing application and received acceptance for the new indication.- Yilishu (Efbemalenograstim Alfa Injection) was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs. In December 2023, Efbemalenograstim alfa was successfully included in the National Reimbursement Drug List (“NRDL”), and its sales volume accelerated in the first half of 2024, becoming an important contributor to the Group’s revenue growth.- Andewei (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody that was approved by the NMPA in April 2024 for use in combination with anlotinib, carboplatin, and etoposide in the first-line treatment of extensive-stage small cell lung cancer.- Anboni (Unecritinib Fumarate Capsules) is a small molecule inhibitor of tyrosine kinase ROS1/ALK/c-Met, which was approved by the NMPA in April 2024 for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer. It is the first domestically produced targeted drug approved for the treatment of ROS1-positive non-small cell lung cancer.- The clinical trial application of Lanifibranor was submitted to and accepted by CDE in March 2023. In July, Lanifibranor was included in the list of breakthrough therapeutics. Currently, Lanifibranor is conducting Phase III clinical trials globally and is actively advancing the enrollment of subjects. Lanifibranor is China's first oral MASH drug to enter Phase III clinical trials and is expected to fill the gap in China's MASH market.HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the “Period”).During the Period, the Group recorded revenue of approximately RMB15.87 billion, a year-on-year increase of approximately 11.1%. Profit attributable to owners of the parent company was approximately RMB3.02 billion, a year-on-year increase of approximately 139.7%. Earnings per share attributable to owners of the parent company were approximately RMB16.39 cents. The significant year-over-year increase in profit attributable to owners of the parent company was mainly due to the gain on disposal of subsidiaries under discontinued operations during the current Period. Adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.54 billion, a YOY increase of approximately 14.0%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB8.55 billion, bank deposits classified as non-current assets of approximately RMB9.18 billion, and wealth management products of approximately RMB4.61 billion in total, and total fund reserves amounting to approximately RMB22.34 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK3 cents per share (1H2023: HK2 cents).Miss Tse, Theresa Y Y, Executive Director and ChairwomanSales: Entering harvesting of innovative results period and sales revenue from generic products further risesAlways placing utmost importance on research and development (“R&D”), the Group leverages in-depth research and development to achieve significant benefits. At present, the Group has entered the harvest period of its innovative development, driving further growth in sales revenue. During the Period, sales of oncology drugs increased by 19.5% year-on-year to approximately RMB5.36 billion, accounting for approximately 33.8% of the Group's revenue. Sales of surgical/analgesic medications increased by 29.9% year-on-year to approximately RMB2.58 billion, accounting for approximately 16.3% of the Group's revenue. Sales of liver disease drugs amounted to approximately RMB2.03 billion, accounting for approximately 12.8% of the Group's revenue. In addition, the sales contributions of products in various areas such as respiratory system, cardio-cerebral vascular medicines, and others increased simultaneously, accounting for approximately 11.2%, 8.6%, and 17.3% of the Group's total revenue, respectively.In the field of respiratory system, The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the volume-based procurement (VBP), enabling Tianqing Suchang’s sales to achieve steady growth during the Period. In the meanwhile, the Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly during the Period.In the field of surgery/analgesia, the Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth during the Period.Mr. Tse, Eric S Y, Executive Director and Chief Executive OfficerR&D: R&D as the core for driving the Group's continuous innovation and developmentThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver disease, respiratory system and surgery/analgesia. As at the end of the reporting Period, the Group had 76 innovative products in development, including 46 oncology products, 6 liver disease products, 9 respiratory system products, 5 surgery/analgesia products, and 10 other products. In addition, the Group had 65 generic drug products in development.The Group has always put R&D at its core, and has continuously improved its R&D capabilities and speed by embracing the R&D concept of combining independent innovation, collaborative development, and the development of both innovative and generic drugs. It considers R&D as the foundation of its sustainable development. In the first half of 2024, it incurred R&D expenses of approximately RMB 2.58 billion, accounting for approximately 16.2% of the Group’s revenue. It is expected that the number of innovative products launched to the market will reach 25 by 2026. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for long-term sustainable growth.Sino Biopharmaceutical ManagementProspects: Keep up with national development strategy and accelerate globalization processThe pharmaceutical industry has become one of the fastest growing and most promising fields in China and even the world. As the world’s second largest pharmaceutical market, China’s demand for medical and healthcare products has grown rapidly in recent years, with breakthroughs being made in biotechnology. Innovation has become a new driving force for the high-quality development of China’s pharmaceutical industry. The Group has been closely monitoring the development of the country, society and the industry, and has continuously optimized its development strategy. Under the four main strategies of “organizational integration, comprehensive innovation, internationalization, and digitalization”, the Group will actively innovate its organizational structure, comprehensively improve its operational efficiency, focus on the innovation and development of the four main therapeutic areas of oncology, liver disease, respiratory system, and surgery/analgesia, and actively accelerate the global deployment of its business.The Group is committed to its mission of becoming a “leading global pharmaceutical company through delivering innovative therapies for patients”. It strives to promote innovative development through its dual engines of internal R&D and business development. Over the years, the Group has stepped up its R&D investment and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. In April 2024, the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the Mainland Chinese market. This move not only demonstrates The Group's innovative strength in the pharmaceutical field, but also reflects its far-reaching influence in international cooperation.Looking ahead, The Group will adhere to its dual-pronged approach in the implementation of its globalization strategy. Through this approach, the Group will bring global pharmaceutical innovations to China to benefit Chinese patients, and also go global and open up new markets to accelerate the satisfaction of unmet clinical needs worldwide. Copyright 2024 ACN Newswire via SeaPRwire.com.

重点成果- 期内，集团共有4个创新产品获中国国家药品监督管理局（「NMPA」）批准上市，分别为安得卫（贝莫苏拜单抗注射液）、安柏尼（富马酸安奈克替尼胶囊）、安洛晴（枸橼酸依奉阿克胶囊）和贝乐林（利拉鲁肽注射液），其中3个为国家1类创新药。- 2024年上半年，集团创新产品收入达到61.3亿元，同比增长14.8%。除创新产品外，集团还有11个仿制药获NMPA批准上市，整体仿制药收入在2024年上半年已实现正增长。新产品是驱动集团收入增长的重要动力，2024年上半年集团5年内上市的新产品收入达到60.3亿元，同比增长39.6%。- 截至2024年6月30日，集团共有43个肿瘤领域、8个呼吸系统领域、6个肝病领域和4个外科╱镇痛领域的创新候选药物处于临床申请及以上开发阶段。其中，3个肿瘤领域、1个外科╱镇痛领域产品处在上市申请阶段；5个肿瘤领域、1个呼吸系统领域、1个肝病领域、1个外科╱镇痛领域的创新候选药物处于临床III期；另有18个肿瘤领域、3个肝病领域、21个呼吸系统领域、10个外科╱镇痛领域的生物类似药或仿制药候选药物处于临床申请及以上开发阶段。- 福可维（盐酸安罗替尼胶囊）是一种新型小分子多靶点酪氨酸激酶抑制剂。2024年2月和7月，安罗替尼联合贝莫苏拜单抗向中国国家药品监督管理局药品审评中心（「CDE」）递交两项新适应症上市申请，分别用于治疗二三线子宫内膜癌和一线肾细胞癌。2024年7月，安罗替尼联合化疗用于晚期软组织肉瘤一线治疗的III期临床研究取得阳性结果，集团已递交新适应症上市申请并获受理。- 亿立舒（艾贝格司亭α）注射液于2023年5月获批用于预防和治疗肿瘤患者在接受化疗药物后出现的中性粒细胞减少症。2023年12月，亿立舒被成功纳入国家医保目录，并在2024年上半年加速放量，成为集团收入增长的重要贡献品种。- 安得卫（贝莫苏拜单抗注射液）是一款人源化PD-L1单克隆抗体，于2024年4月获得NMPA的上市批准，用于联合安罗替尼、卡铂和依托泊甘一线治疗广泛期小细胞肺癌。- 安柏尼（富马酸安奈克替尼胶囊）是一款酪氨酸激酶ROS1/ALK/c-Met小分子抑制剂，于2024年4月获得NMPA的上市批准，用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌，是首个获批用于治疗ROS1阳性非小细胞肺癌的国产靶向药。- 拉尼兰诺（泛PPAR激动剂）于2023年3月向CDE递交临床试验申请并获得受理，7月，拉尼兰诺被CDE纳入突破性治疗品种名单。目前该产品正在全球进行III期临床试验，是中国第一个进入临床III期的MASH口服药物，有望填补中国MASH市场空白。香港, 2024年8月14日 - (亚太商讯 via SeaPRwire.com) – 中国领先的创新研发驱动型医药集团—中国生物制药有限公司（「中国生物制药」或「公司」，连同附属公司统称「集团」）（股票编号：1177）公布截至2024年6月30日止6个月（「期内」）之未经审核财务业绩。回顾期内，集团收入同比增长11.1%至约158.7亿元（人民币，下同）。归属于母公司持有者应占盈利约30.2亿元，同比增长约139.7%，基于归属于母公司持有者应占盈利计算之每股盈利约16.39分。归属于母公司持有者盈利同比显著增加主要由于本期间录得处置附属公司收益并计入已终止经营业务导致。经调整非《香港财务报吿准则》归母净利润约15.4亿元，同比增长约14.0%。集团流动资金保持充裕，期内有计入流动资产之现金及银行结余约85.5亿元、计入非流动资产之银行存款约91.8亿元，理财管理产品总额约46.1亿元，资金储备合共约223.4亿元。董事会建议派发中期股息每股3港仙（2023上半年：2港仙）。中国生物制药董事会主席谢其润女士销售：迈入创新成果收获期 创新产品销售收入持续增加集团一直以来重视研发，并凭借高研发投入以获得显著收益。集团现已步入创新成果密集收获期，带动销售收入进一步增长。期内，抗肿瘤用药之收入同比增加19.5%，达约53.6亿元，占集团收入约33.8%。外科／镇痛用药之收入同比增加29.9%，达约25.8亿元，占集团收入约16.3%。肝病用药收入录得约20.3亿元，占集团收入12.8%。此外，呼吸系统、心脑血管用药和其他等不同领域产品的销售贡献多轮并进，分别占集团收入约11.2%、8.6%和17.3%。于呼吸系统领域，集团及时采取了一系列主动管理措施，包括管道下沉、拓展市场覆盖和集采外市场的二次开发，使天晴速畅销售额于期内实现了稳步增长。同时，集团通过积极的学术推广，不断拓展市场覆盖，令天韵的销售额于期内亦取得快速增长。于外科╱镇痛领域，集团聚焦高潜地区开发，深入拓展市场覆盖，并逐步扩大产能，以满足市场的旺盛需求。氟比洛芬凝胶贴膏的销售额在过去几年保持增长态势，并在期内实现了突破性增长。中国生物制药董事会首席执行长谢承润先生研发：以研发为核心，驱动集团持续创新与发展集团继续专注肿瘤、肝病、呼吸系统和外科╱镇痛四大治疗领域的新产品研发。截至报告期日，集团有在研创新产品76个，其中肿瘤用药46个、肝病用药6个、呼吸系统用药9个、外科╱镇痛用药5个，其他类用药10个。另外，集团还有65个在研仿制药产品。集团始终将研发置于核心位置，秉承自主创新、联合开发及创仿开发相结合的研发策略，持续提高研发能力和效率，将其视为企业持续发展的关键。2024年上半年集团研发费用达到约25.8亿元，占集团收入约16.2%。预计到2026年，已上市创新产品的数量将达到25个，将进一步强化集团在四大治疗领域的优势地位，为长期可持续增长注入强大动力。中国生物制药管理层展望：紧跟国家发展战略，加速国际化进程医药行业已成为中国乃至全球最具活力和发展潜力的领域之一。中国作为全球第二大医药市场，近年来医疗健康需求的快速增长和生物技术的持续突破，为医药产业的高质量发展注入了新动力。集团紧跟国家、社会及行业的最新动态，不断优化发展策略，以「组织整合、全面创新、国际化、数字化」为四大战略方向，积极革新组织架构，全面提升运营效率，专注于肿瘤、肝病、呼吸、外科/镇痛四大治疗领域的创新发展，并大力推进国际化布局。集团秉承「专注创新、服务病患，成为全球领先的制药企业」的愿景，通过自主研发和商务拓展的双引擎驱动，不断推动创新发展。集团不断加大研发投入，积累了强大的自主研发能力。同时，集团积极推进商务拓展和战略合作，力争成为全球制药与生物科技公司的的最佳合作伙伴。2024年4月，集团与勃林格殷格翰建立战略合作伙伴关系，将勃林格殷格翰的创新抗肿瘤疗法引入中国大陆市场，这一举措不仅展现了集团在医药领域的创新实力，也体现了其在国际合作中的深远影响力。展望未来，集团将持续坚守「引进来」与「走出去」的双重策略，以实现国际化发展。集团将全球的医药创新成果引入中国，为中国的病患带来福祉；同时也将积极开拓新的市场，以加速满足全球各地未被满足的临床需求。 Copyright 2024 亚太商讯 via SeaPRwire.com.